Yoshizaki, Tomokazu

Pembrolizumab alone or with chemotherapy versus cetuximab with chemotherapy for recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-048): a randomised, open-label, phase 3 study

Burtness, B., Harrington, K. J., Greil, R., Soulières, D., Tahara, M., de Castro, G., Psyrri, A., Basté, N., Neupane, P., Bratland, Å., et al. (2019) · The Lancet

Head and Neck Cancer StudiesCancer Immunotherapy and Biomarkers

Cited by 3,336

Deletion of CD38 and supplementation of NAD+ attenuate axon degeneration in a mouse facial nerve axotomy model

Takaso, Y., Noda, M., Hattori, T., Roboon, J., Hatano, M., Sugimoto, H., Brenner, C., Yamamoto, Y., Okamoto, H., Higashida, H., et al. (2020) · Scientific Reports

Nerve injury and regenerationFacial Nerve Paralysis Treatment and Research

Cited by 17